NCT02060929View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

Esketamine

Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02060929 - A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device | Biotech Hunter | Biotech Hunter